See how OWLiver provides deeper, non-invasive insight to support more informed clinical decisions.
Earlier Insight Can Inform What Happens Next
Fatty liver disease or metabolic dysfunction-associated steatotic liver disease (MASLD) affects a broad and growing patient population, particularly among individuals with obesity, type 2 diabetes, metabolic syndrome, insulin resistance or dyslipidemia. Yet MASLD often presents without symptoms, and liver enzyme levels alone may not reveal the presence or severity of the disease.
Identifying fatty liver is only the beginning. To guide appropriate care, clinicians need to understand where a patient falls along the disease spectrum, from steatosis to to MASH with significant fibrosis.
Earlier, more complete assessment can help clinicians:
• Identify patients at greater risk of disease progression
• Determine who may benefit from treatment or specialist referral
• Support informed conversations about lifestyle and therapeutic interventions
• Establish a baseline for monitoring changes over time
Looking Beyond Conventional Assessment
Some non-invasive tests can help identify the risk of advanced fibrosis, but they may not provide insight across all clinically meaningful stages of MASLD. Liver biopsy offers detailed diagnostic information, yet its invasive nature can make it impractical for broad assessment or routine monitoring.
OWLiver offers another approach.
Using a simple blood sample, OWLiver analyzes a panel of 28 metabolic biomarkers associated with liver fat, inflammation and fibrosis. The test is designed to identify MASLD, MASH with moderate or no fibrosis (F0–F1), and MASH with significant fibrosis (F≥2).
Validated against liver biopsy, OWLiver provides a clear, easy-to-interpret report that helps clinicians see where a patient may fall within the MASLD spectrum without an invasive procedure.
Better Information Supports Wiser Decisions
As the treatment landscape continues to evolve, identifying disease earlier may create an important opportunity to intervene before significant liver damage occurs. Deeper insight can help clinicians determine the appropriate next step for each patient, whether that means closer monitoring, lifestyle intervention, treatment consideration or referral to a liver specialist.
Because when clinicians can see more of the story, they are better equipped to help change its course.